RespireRx Pharmaceuticals (RSPI) 8-K Cortex Reports Second Quarter Results

Exhibit 99.1

PRESS RELEASE

Company Contact:	Investor Contact:
Roger G. Stoll, Ph.D. Chairman, President and CEO Cortex Pharmaceuticals, Inc. 949.727.3157	Damian McIntosh/ Dian Griesel, Ph.D. The Investor Relations Group 212.825.3210

CORTEX REPORTS SECOND QUARTER RESULTS

IRVINE, CA (August 15, 2005) — Cortex Pharmaceuticals, Inc. (AMEX: COR) reported a net loss of $2,689,000 ($0.08 per share) for the quarter ended June 30, 2005, compared with a net loss of $1,314,000 ($0.05 per share) for the corresponding prior year period. For the six months ended June 30, 2005, Cortex reported a net loss of $5,337,000 ($0.16 per share) compared with a net loss of $2,188,000 ($0.08 per share) for the corresponding prior year period. Increased net losses in the current year periods reflect development expenses for the AMPAKINE^® compound, CX717 and increased preclinical research and development of the AMPAKINE technology. Cortex expects that the increased pace of research and development will continue to impact its expense levels throughout 2005.

As recently reported, Cortex has begun enrollment in its second and third Phase IIa studies with CX717: one in Attention Deficit Hyperactivity Disorder and the other in mild to moderate Alzheimer’s disease. These studies follow results from the first Phase IIa trial with CX717 that suggest that when compared to placebo, the compound increased wakefulness in a dose-related manner and improved cognitive performance in healthy male subjects that were deprived of sleep. A fourth Phase IIa study in simulated night shift work is scheduled to start enrollment at the end of August. Cortex anticipates that information relative to the outcome of these studies will be available toward the end of 2005 or sooner, depending on patient enrollment.

Revenues of $647,000 and $1,346,000 for the three months and six months ended June 30, 2005, respectively, decreased relative to the prior year periods due to the end of research support under the October 2002 amendment to Cortex’s collaborative agreement with Servier. Revenues for the current year periods primarily represent the research support that Cortex continues to receive from Servier under the October 2000 collaborative agreement, as extended in late 2003.

A conference call to discuss the quarterly results and the continuing developments within Cortex’s research and development is scheduled for August 17 at 3:00 pm EDT. Participants are asked to call the following numbers 5-10 minutes prior to the starting time:

• From the U.S. and Canada: 1-800-925-2151

• International: 1-913-981-5552

A replay will be available for 45 days after the call by dialing 1-888-203-0820 (US and Canada) or 1-719-457-0820 (International) and entering access code 9450020 when prompted.

Cortex Pharmaceuticals, Inc.

Cortex, located in Irvine, California, is a neuroscience company focused on novel drug therapies for neurological and psychiatric disorders. The Company is pioneering a class of proprietary pharmaceuticals called AMPAKINE compounds, which act to increase the strength of signals at connections between brain cells. The loss of these connections is thought to be responsible for memory and behavior problems in Alzheimer’s disease. Many psychiatric diseases, including schizophrenia, occur as a result of imbalances in the brain’s neurotransmitter system. These imbalances may be improved by using the AMPAKINE technology. Cortex has alliances with N.V. Organon for the treatment of schizophrenia and depression and with Les Laboratoires Servier for the development of AMPAKINE compounds to treat the neurodegenerative effects associated with aging and disease, including Mild Cognitive Impairment, Alzheimer’s disease and anxiety disorders.

Forward-Looking Statement

Note — This press release contains forward-looking statements concerning the Company’s research and development activities. The success of such activities depends on a number of factors, including the risks that the Company’s proposed products may at any time be found to be unsafe or ineffective for any or all of their proposed indications; that competitors may challenge or design around the Company’s patents or develop competing technologies; and that clinical studies may at any point be suspended or take substantially longer than anticipated to complete. As discussed in the Company’s Securities and Exchange Commission filings, the Company’s proposed products will require additional research, lengthy and costly clinical testing and regulatory approval. AMPAKINE compounds are investigational drugs and have not been approved for the treatment of any disease.

(tables follow)

Cortex Pharmaceuticals, Inc.

Condensed Statements of Operations

(in thousands, except per share data)

(Unaudited)

	Three months ended June 30,						Six months ended June 30,
	2005			2004			2005			2004
Revenues	$	647		$	1,213		$	1,346		$	2,379
Operating expenses:
Research and development		2,738			2,083			5,374			3,247
General and administrative		696			513			1,479			1,136
Non-cash stock compensation charges		55			35			61			216
Total operating expenses		3,489			2,631			6,914			4,599
Loss from operations		(2,842	)		(1,418	)		(5,568	)		(2,220	)
Interest income, net		153			104			314			136
Increase in fair value of common stock warrants		—			—			(64	)		—
Amortization of capitalized financing costs		—			—			(19	)		(104	)
Net loss applicable to common stock	$	(2,689	)	$	(1,314	)	$	(5,337	)	$	(2,188	)
Loss per share:
Basic and diluted	$	(0.08	)	$	(0.05	)	$	(0.16	)	$	(0.08	)
Shares used in basic and diluted calculation		32,660			28,297			32,643			26,295

Cortex Pharmaceuticals, Inc.

Condensed Balance Sheets

(in thousands)

	June 30, 2005 (Unaudited)		December 31, 2004
Assets:
Cash and cash equivalents	$	880	$	9,157
Marketable securities		21,678		18,838
Accounts receivable		9		42
Other current assets		230		318
		22,797		28,355
Furniture, equipment and leasehold improvements, net		472		388
Capitalized financing costs		—		1,136
Other		33		33
Total assets	$	23,302	$	29,912
Liabilities and stockholders’ equity:
Accounts payable and accrued expenses	$	1,790	$	1,907
Unearned revenue — current		137		377
Non-current liabilities		98		23
Common stock warrants		—		3,958
Stockholders’ equity		21,277		23,647
Total liabilities and stockholders’ equity	$	23,302	$	29,912

MOREINFORMATIONATWWW.CORTEXPHARM.COM

#    #    #    #    #